Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07049978 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-term Effect of Dupilumab in N-ERD

StatusCompleted
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completed without a posted recruiting period Final enrollment: 15 participants (planned 30) · Primary completion date changed from estimate of Jun 30, 2026 to May 7, 2026 · Start date changed from estimate of Jul 1, 2025 to Sep 1, 2025 · 3 more Show 6 more changesShow less
    • Final enrollment: 15 participants (planned 30)
    • Primary completion date changed from estimate of Jun 30, 2026 to May 7, 2026
    • Start date changed from estimate of Jul 1, 2025 to Sep 1, 2025
    • Eligibility criteria expanded, about 10 words
    • Site contact updated
    • Publications: details revised at 1 of 1 entry
  2. Secondary endpoints: 6 to 5 Site details revised · Publications: details revised at 1 of 1 entryv2 Show 2 more changesShow less
    • Site details revised
    • Publications: details revised at 1 of 1 entry

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This prospective observational study investigates the long-term effects of Dupilumab in patients with NSAID-exacerbated respiratory disease (N-ERD). The study assesses changes in ASA tolerance, clinical parameters, inflammatory biomarkers, quality of life, and nasal microbiome during ongoing treatment with Dupilumab. All participants are receiving Dupilumab as part of standard clinical care.
Trial Details
NCT Number NCT07049978
Lead Sponsor Medical University of Vienna
Conditions NSAID-Induced Asthma, NSAIDs Hypersensitivity, Chronic Rhinosinusitis (CRS), Asthma Bronchiale, Nasal Polyposis
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov